XML 74 R49.htm IDEA: XBRL DOCUMENT v3.25.0.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Revenue by Geographical Region (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disaggregation of Revenue [Line Items]      
Revenue $ 837.6 $ 753.2 $ 678.4
Hereditary Cancer      
Disaggregation of Revenue [Line Items]      
Revenue 364.5 327.8 305.5
Tumor Profiling      
Disaggregation of Revenue [Line Items]      
Revenue 125.8 135.6 128.6
Prenatal      
Disaggregation of Revenue [Line Items]      
Revenue 177.1 151.3 116.4
Pharmacogenomics      
Disaggregation of Revenue [Line Items]      
Revenue 170.2 138.5 127.6
Autoimmune      
Disaggregation of Revenue [Line Items]      
Revenue 0.0 0.0 0.3
United States      
Disaggregation of Revenue [Line Items]      
Revenue 769.5 671.7 591.5
United States | Hereditary Cancer      
Disaggregation of Revenue [Line Items]      
Revenue 318.6 280.5 263.5
United States | Tumor Profiling      
Disaggregation of Revenue [Line Items]      
Revenue 104.2 102.1 84.5
United States | Prenatal      
Disaggregation of Revenue [Line Items]      
Revenue 176.5 150.6 115.6
United States | Pharmacogenomics      
Disaggregation of Revenue [Line Items]      
Revenue 170.2 138.5 127.6
United States | Autoimmune      
Disaggregation of Revenue [Line Items]      
Revenue 0.0 0.0 0.3
Rest of world      
Disaggregation of Revenue [Line Items]      
Revenue 68.1 81.5 86.9
Rest of world | Hereditary Cancer      
Disaggregation of Revenue [Line Items]      
Revenue 45.9 47.3 42.0
Rest of world | Tumor Profiling      
Disaggregation of Revenue [Line Items]      
Revenue 21.6 33.5 44.1
Rest of world | Prenatal      
Disaggregation of Revenue [Line Items]      
Revenue 0.6 0.7 0.8
Rest of world | Pharmacogenomics      
Disaggregation of Revenue [Line Items]      
Revenue 0.0 0.0 0.0
Rest of world | Autoimmune      
Disaggregation of Revenue [Line Items]      
Revenue $ 0.0 $ 0.0 $ 0.0